Event-Driven Stocks

Repare Therapeutics Inc.

RPTX

Healthcare · Pharmaceutical Preparations · Z4 · SEC filings ↗ · Compare ⊕

View price & chart on Yahoo Finance ↗
Signs● 2 good● 1 warning● 1 severedetails ↓

Financials

SEC XBRL · annual
 FY24FY23FY22FY21FY20FY19
Revenue——————
Operating income−$93.5M−$116.2M−$19.8M−$108.7M−$54.3M−$26.4M
Net income−$84.7M−$93.8M−$29.0M−$106.9M−$53.4M−$27.2M
Total assets$176.5M$253.9M$364.1M$368.7M$357.1M$102.7M
Total liabilities$25.4M$41.8M$84.6M$80.3M$70.3M$12.8M
Equity$151.1M$212.1M$279.5M$288.4M$286.8M−$46.1M
EPS (diluted)$-2.00$-2.23$-0.69$-2.83——
Shares out.42.2M42.1M41.9M36.9M36.9M1.5M

Reported figures from the company's SEC filings (XBRL). Blank where a line item isn't cleanly tagged — never estimated.

Key ratios

from filings · FY2024
Operating margin
—
Net margin
—
Return on equity
−56.0%
Return on assets
−48.0%
Return on capital (ROCE)
−61.8%
Liabilities / assets
14.4%
Debt / equity
0.17×
Book value / share
$3.58
Revenue growth (YoY)
—
Net income growth (YoY)
—

Computed from the company's own SEC figures — no market price, so these are facts, not a valuation. Book value per share is reported equity ÷ shares; it is not the stock price.

Financial health

forensic scores · FY2024
Altman Z″ (distress)
0.40distress
Accruals / assets
−4.7%clean
Piotroski F-Score
3/7weak

Altman Z″is a textbook bankruptcy-distress score from book values only (>2.6 safe · 1.1–2.6 grey · <1.1 distress). Accruals = (net income − operating cash flow) ÷ assets; persistently high accruals are an earnings-quality red flag. Beneish M-Scoreis an eight-ratio screen comparing this year with last (M > −1.78 = elevated manipulation-risk screen, not proof). Piotroski F-Scorecounts how many of nine fundamental-health checks pass (shown as passed / applicable; we use operating margin and total liabilities as documented proxies where the exact input isn't XBRL-tagged). Computed from SEC filings — descriptive factors, not advice or a forecast.

Quality score

EDS Score
52
/ 100
Profitability 0Growth n/aCatalyst 67Earnings quality 67Financial strength 75

Our own multi-factor score from free SEC data — profitability, growth, financial strength, earnings quality, and event/ownership catalysts. No market price and no licensed model: each axis is the share of source-backed checks it passes. Descriptive factors, not advice or a forecast.

Signs

● 1 severe● 1 warning● 2 good
  • Altman Z″ in the distress zone
  • Negative operating cash flow
  • Conservative leverage (liabilities < 50% of assets)
  • Clean earnings (low accruals)

Derived from the company's own SEC figures (fundamentals, forensic scores, filing discipline) — descriptive factors, not advice or a forecast.

5%+ owners

SEC Schedule 13D / 13G · last 3 yrs

Holders who disclosed a 5%+ stake. 13D signals intent to influence or control; 13G is a passive holding. Latest filing per holder — open it for the exact stake.

Short interest

FINRA · bi-monthly
SettlementShares shortDays to coverΔ vs prior
Jan 15, 2026437,8961.0+125.3%
Dec 31, 2025194,3361.0-44.9%
Dec 15, 2025352,3611.0+2.2%
Nov 28, 2025344,7731.0-35.4%
Nov 14, 2025533,6371.2-1.0%

Shares sold short as reported to FINRA. Days-to-cover = short shares ÷ average daily volume — higher means more potential squeeze pressure.

Material events

SEC Form 8-K · most recent

Events the company reported on Form 8-K, labelled by the SEC item code it filed under — its own classification, not our interpretation.

Recent SEC filings

All filings ↗

Event-driven situations (2)